Maastricht University
Maastricht, Netherlands
NCT Number: NCT02173002
Inflammatory bowel diseases (IBD) is an invalidating disease mainly diagnosed in young people. The disease is characterized by a heterogenic phenotype and the disease course by flares and remissions. As in most chronic diseases the economic burden of IBD is important due to direct health care costs and disability. Health care reorganization for IBD patients in the Netherlands is necessary for several reasons. First chronic (sub)clinical mucosal inflammation results in irreversible bowel damage and complications and none of the presently available drugs is effective for all patients and many drugs have possible severe side effects. To prevent complications of the disease and side effects IBD should be monitored carefully. In the Netherlands however there is a shortage of gastroenterologists where the incidence of IBD is rising. Secondly evidence exists that direct involvement of health care workers, patient empowerment and integrated care can improve the outcome of chronic diseases. Thirdly many clinically relevant aspects (e.g. malnutrition) of this complex disease are not systematically followed in routine care. Finally the government demands registration of efficacy endpoints for expensive drugs in the near future. Therefore the investigators developed a web-based Telemedicine tool for IBD patients in collaboration with the Dutch IBD patient's organization (CCUVN). "myIBcoach" contains E-learning modules, monitors disease activity, disability, quality of life, adherence, infections, smoking status, side effects, stress and malnutrition on fixed time points with validated questionnaires, allows the patient to communicate with health care workers and gives feedback to the back office and the patient. A feasibility study in 30 IBD patients in 3 centres showed a high satisfaction and compliance of IBD-patients and health care workers with this telemedicine tool.
The aim of this study is to compare standard care for IBD patients in 3 hospitals with a care via the telemedicine tool myIBDcoach.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Maastricht, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 year
Amount of outpatient hospital visits between the two study-arms
Time frame: 1 year
Questionnaire: Patient reported satisfaction with IBD care 0-10
Time frame: 1 year
Hospital admission rate
Time frame: 1 year
Time frame: 1 year
Questionnaire: patient reported quality of care 0-10
Time frame: 1 year
Questionnaire: How do you score your IBD specific knowledge on a scale from 0-10?
Time frame: 1 Year
Questionnaire: How do you score your knowledge about the medication you use on a scale from 0-10?
Time frame: 1 year
Morisky Medication Adherence Scale
Time frame: 1 year
Short IBD questionnaire EQ-6D
Time frame: 1 year
Monitor IBD At Home score
Time frame: 1 year
Change of smoking habits after 1 year
Time frame: 1 year
Questionnaire every 3 months
Time frame: 1 year
IBD self-efficacy scale
Maastricht University Medical Center
Other
Acronym: myIBDcoach
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02136745
Colonic Diseases, Colonic Diseases, Functional
Boston, Massachusetts, United States
View Trial DetailsNCT02847052
Digestive System Diseases, Gastroenteritis
Nantes, France
View Trial DetailsNCT04060303
Colitis, Colitis, Ulcerative
Chicago, Illinois, United States
View Trial DetailsNCT02341742
Behavior, Digestive System Diseases
Lille, Nord, France
View Trial Details